Dual Source Ion Mobility-Mass Spectrometer

项目摘要/摘要： Bruker timsTOF FLEX包括一台液色仪(LC)，基质辅助激光解吸电离 (MALDI-2)和电喷雾电离(ESI)源、俘获离子迁移率光谱仪(TIMS)和四极杆- 飞行时间(QTOF)质谱仪组合成一台仪器，可以分析代谢物、血脂和 含量高或产量高的蛋白质。最重要的是，这两个实验之间的差距可以 当两者在同一仪器上进行时，很容易连接起来；例如，代谢组学数据可以 有效地与质谱仪成像相结合。为了描述单独的成分，液体 色谱仪提供分析物的分离，以增加蛋白质组和代谢组采样的深度。这个 两个离子源可用于分析液体样品(ESI)或与基质共结晶的样品阵列 (MALDI)。俘获离子迁移谱仪(TIMS)为碰撞截面(CCS)提供了数据 计算以进一步定义每个分析物以及将分子气相浓缩成小包 用于质量分析的相似的CCS-电荷比。QTOF提供质谱学和串联质谱学 具有高分辨率和精确质量测量的光谱。供应商软件提供以下支持 代谢组学和蛋白质组学的数据分析以及质谱学的可视化和分析 成像。将该仪器加入我们的蛋白质组学和代谢组学核心(P&MC)是对我们的补充 现有的LC-MS资源，为离子迁移率-质谱学提供了新的能力，取代了MALDI 去年退役的仪器，并增强了可用于质谱分析的资源 成像。由于肿瘤的异质性、肿瘤-免疫界面和分析物在肿瘤中的空间分布 现在越来越重要，必须修改现有的分析平台以满足这些需求 还需要对仪器设备进行更多投资。Bruker timsTOF FLEX是对现有LC-MS的补充 通过降低样本投入要求来衡量和优化新技术投资的价值， 创造组织空间组学能力，支持MALDI-TIMS-MS高通量筛查，以及 异构体脂类、代谢物和翻译后修饰或化学标记的离子迁移率分离 多肽。布鲁克提供的例子已经得到了我们自己样品的示范数据的证实。 该设备还可以用于改进生物标记物的发现，并将分子测量与 传统的病理工作流程。安置在核心设施中，拥有训练有素的工作人员和广泛的 机构支持将最大限度地提高用户组的可用性，并使他们从访问 乐器。总而言之，这些优势有望显著推动癌症代谢组学和 莫菲特癌症中心的蛋白质组学应用程序，以支持NIH/NCI资助的现有和计划中的研究和 推动癌症代谢计划的发展，以制定针对肿瘤脆弱性的战略。

Project Summary/Abstract: The Bruker timsTOF fleX includes a liquid chromatograph (LC), matrix assisted laser desorption ionization (MALDI-2) and electrospray ionization (ESI) sources, trapped ion mobility spectrometer (tims), and quadrupole- time-of-flight (QTOF) mass spectrometer combined into an instrument that can analyze metabolites, lipids, and proteins with high content or high throughput. Most importantly, the gap between these two experiments can be bridged easily when both are conducted on the same instrument; for example, metabolomics data can be effectively integrated with mass spectrometry imaging. To describe the individual components, the liquid chromatograph provides separation of analytes to increase depth of proteome and metabolome sampling. The two ion sources enable analysis of liquid samples (ESI) or arrays of samples co-crystallized with matrix (MALDI). The trapped ion mobility spectrometer (tims) provides data for collision cross section (CCS) calculations to further define each analyte as well as gas phase enrichment of molecules into packets with similar CCS-to-charge ratios for mass analysis. The QTOF provides mass spectrometry and tandem mass spectrometry with high resolution and accurate mass measurement. Vendor software provides support for data analysis in both metabolomics and proteomics as well as visualization and analysis of mass spectrometry imaging. The addition of this instrument to our Proteomics & Metabolomics Core (P&MC) complements our existing LC-MS resources, provides novel capability for ion mobility-mass spectrometry, replaces a MALDI instrument that was decommissioned last year, and enhances resources available for mass spectrometry imaging. As tumor heterogeneity, the tumor-immune interface, and spatial distribution of analytes in tumors now have increasing importance, existing analytical platforms must be modified to meet these needs and additional investments in instrumentation are needed. The Bruker timsTOF fleX complements existing LC-MS instruments and optimizes the value of investment in new technology by lowering sample input requirements, creating capability for spatial omics of tissues, supporting high throughput screening with MALDI-tims-MS, and ion mobility separation of isomeric lipids, metabolites, and post-translationally modified or chemically labeled peptides. Examples provided by Bruker have been confirmed by demonstration data from our own samples. This device also can be used to improve biomarker discovery and integrate molecular measurements with traditional pathology workflows. The placement in a core facility with highly trained staff and extensive institutional support will maximize both the availability to the user group and their benefit from access to the instrument. Together, these advantages are expected to significantly advance cancer metabolomics and proteomics applications at Moffitt Cancer Center to support existing and planned NIH/NCI-funded research and fuel the development of a Cancer Metabolism Program to develop strategies to target tumor vulnerabilities.